The molecular genetic makeup of acute lymphoblastic leukemia

December 08, 2012

Dr. Charles Mullighan surveys the large collection of genetic alterations revealed from these studies in childhood ALL and explains how some of these alterations may be used to understand and predict treatment failure, as well as provide novel diagnostic markers and therapeutic targets. For example, patients harboring alterations commonly associated with poor treatment outcomes, such as IKZF1, may benefit from tyrosine kinase inhibitor therapy if kinase-activating alterations are also present. Investigators are currently defining the genetic landscape of ALL, and some key challenges ahead will be functionally validating the alterations driving ALL etiology and biology, as well as implementing practical clinical strategies derived from the genetic information.


Last updated: October 30, 2018